Natus Medical Inc (NASDAQ:BABY) Stock Position Trimmed by Prudential Financial Inc.

Share on StockTwits

Prudential Financial Inc. cut its position in Natus Medical Inc (NASDAQ:BABY) by 8.7% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 55,311 shares of the medical equipment provider’s stock after selling 5,240 shares during the quarter. Prudential Financial Inc.’s holdings in Natus Medical were worth $1,421,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of BABY. SG Americas Securities LLC lifted its position in Natus Medical by 231.0% in the 1st quarter. SG Americas Securities LLC now owns 13,884 shares of the medical equipment provider’s stock valued at $352,000 after purchasing an additional 9,690 shares during the last quarter. Comerica Bank lifted its position in Natus Medical by 1.2% in the 1st quarter. Comerica Bank now owns 33,383 shares of the medical equipment provider’s stock valued at $856,000 after purchasing an additional 384 shares during the last quarter. Texas Permanent School Fund lifted its position in Natus Medical by 3.7% in the 1st quarter. Texas Permanent School Fund now owns 22,934 shares of the medical equipment provider’s stock valued at $582,000 after purchasing an additional 828 shares during the last quarter. Piedmont Investment Advisors Inc. lifted its position in Natus Medical by 4.8% in the 1st quarter. Piedmont Investment Advisors Inc. now owns 8,406 shares of the medical equipment provider’s stock valued at $213,000 after purchasing an additional 387 shares during the last quarter. Finally, Martingale Asset Management L P raised its position in shares of Natus Medical by 547.4% during the 1st quarter. Martingale Asset Management L P now owns 141,823 shares of the medical equipment provider’s stock worth $3,601,000 after buying an additional 119,918 shares in the last quarter. Hedge funds and other institutional investors own 91.56% of the company’s stock.

Shares of BABY stock remained flat at $$31.92 during midday trading on Friday. 289,334 shares of the company’s stock were exchanged, compared to its average volume of 165,325. Natus Medical Inc has a one year low of $23.53 and a one year high of $37.90. The stock has a market capitalization of $1.09 billion, a P/E ratio of 22.48 and a beta of 0.57. The business has a 50 day simple moving average of $29.93 and a 200 day simple moving average of $26.88. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.18 and a current ratio of 1.70.

Natus Medical (NASDAQ:BABY) last released its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.30 by $0.04. Natus Medical had a negative net margin of 7.38% and a positive return on equity of 10.79%. The company had revenue of $125.50 million for the quarter, compared to the consensus estimate of $122.85 million. During the same period in the previous year, the firm earned $0.35 EPS. Natus Medical’s revenue was down 4.0% on a year-over-year basis. Equities research analysts predict that Natus Medical Inc will post 1.27 EPS for the current year.

In related news, VP Austin Francis Noll III sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $31.14, for a total value of $622,800.00. Following the sale, the vice president now directly owns 105,193 shares in the company, valued at approximately $3,275,710.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ken Ludlum sold 12,632 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $31.94, for a total transaction of $403,466.08. Following the completion of the sale, the director now owns 39,406 shares in the company, valued at $1,258,627.64. The disclosure for this sale can be found here. 1.65% of the stock is currently owned by insiders.

A number of analysts have commented on the stock. BidaskClub upgraded shares of Natus Medical from a “strong sell” rating to a “sell” rating in a research report on Tuesday, July 23rd. Zacks Investment Research upgraded shares of Natus Medical from a “strong sell” rating to a “hold” rating in a research report on Wednesday, June 26th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company. Natus Medical presently has an average rating of “Hold” and an average price target of $36.00.

Natus Medical Profile

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Featured Article: Why are analyst ratings important in trading stocks?

Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc (NASDAQ:BABY).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.